News

FDA Postmarket Trial for PAH Treatment Bosentan Reveals Drug Does Not Reduce Time To Mortality Rates

Drug maker Actelion has indicated that the company’s Food and Drug Administration (FDA)–approved pulmonary arterial hypertension (PAH) drug Bosentan, which is also known under the brand names of Actelion and Tracleer, recently failed a key FDA postmarket test. The test, which was part of the postmarket COMPASS 2 trial, revealed that Bosentan did not reduce time…

New PAH Treatment Approved for Distribution in Japan

United Therapeutics Corporation has announced that Remodulin, a new treatment for pulmonary arterial hypertension (PAH) by subcutaneous and intravenous administration, has obtained a distribution permit in Japan from the country’s Ministry of Health, Labour and Welfare, the governmental body responsible for granting such approvals. Yu-Lun Lin, associate vice president and managing…

Low-Dose Radiation Leads To Drop In PAR For Idiopathic Pulmonary Arterial Hypertension Patient, According To Study

A novel concept of targeting the autonomic nervous system around pulmonary arteries and activation of vasointestinal peptides (VIP) to treat Idiopathic Pulmonary Arterial Hypertension (IPAH) was recently developed by a group of researchers. The study, published in the online journal Therapeutics and Clinical Risk Management (March 27, 2014), profiled a 58…

Early-Stage Pulmonary Arterial Hypertension Therapy From Pulmokine Awarded $1.5 Million Through Federally Funded VITA Contract

Rensselaer, New York-based biopharmaceutical company Pulmokine recently made a major announcement regarding the company’s efforts in developing a novel therapy for pulmonary arterial hypertension (PAH). In a press release from late March, Pulmokine indicated that that the National Heart, Lung, and Blood Institute (NHLBI), a division of the federally run National…

A Conversation With Rare Disease Advocates